4
ISSUE
posterior segment • innovation • enlightenment
09 | 05 | 22
PIE M A G A ZINE ’ S D A ILY CONGR E S S NE W S ON T HE P O S T E RIOR S E GME N T
HIGHLIGHTS guidelines 04 EURETINA defined trends in the next generation of retinal medicine… from around the 05 Experts globe gathered on the final day of EURETINA 2022 to share the latest insights in diagnosing and treating CSC. cap the congress, 07 Toexperts deep dived into diabetic retina…find out more.
Celebrating
Published by
Years of
Matt Young
CEO & Publisher
Hannah Nguyen COO & CFO
Robert Anderson Media Director
Gloria D. Gamat Chief Editor
Brooke Herron Editor
International Business Development
Ruchi Mahajan Ranga Brandon Winkeler Writers
Hazlin Hassan Matt Herman Maricel Salvador Graphic Designer
Media MICE Pte. Ltd.
6001 Beach Road, #09-09 Golden Mile Tower, Singapore 199589 Tel. Nos.: +65 8186 7677 Email: enquiry@mediamice.com www.mediaMICE.com
piemagazine.org
y p a r e h T F G E V i t n A in n A MD A by Hazlin Hassan
s anti–vascular endothelial growth factor (anti-VEGF) therapy hits the grand old age of fifteen, neovascular age-related macular degeneration (nAMD) has already affected some 20 million people around the world. And the number of people with AMD is predicted to grow to 288 million globally by 2040.
Just like any other teenager, anti-VEGF therapies have notched up a swathe of experiences over the last 15 years, and will have to roll out new strategies to face the challenges ahead.
On Day 4 of the 22nd EURETINA Congress (EURETINA 2022) in Hamburg, Germany, esteemed surgeons around the region gathered to trace its 15-year history in nAMD, discuss how real-world data is helping form treatments, and to take a look at what lies ahead in the future. When they were introduced 15 years ago, antiVEGF therapies were aimed at reducing the rates of visual impairment or blindness due to nAMD. However, data suggests that progression to atrophy and/or fibrosis can occur despite optimal VEGF therapy. Cont. on Page 3 >>